Orphan drug designation granted to Qutenza for postherpetic neuralgia

NeurogesX announced that the FDA has granted orphan drug designation for its drug candidate, Qutenza (capsaicin) dermal patch, for the management of neuropathic pain in patients with postherpetic neuralgia (PHN).  Presently, the FDA is reviewing the company's new drug application (NDA) for Qutenza in PHN.

For more information call (650) 358-3300 or visit www.neurogesx.com.